number nine. a new experimental alzheimer s drug called lacanamab appears to be one of the first to slow the progression of decline. the buildup of this naturally occurring protein can block neural pathways, making it a hallmark of alzheimer s. researchers found that the drug eventually helped reduced amyloid levelses and slowed cognitive decline by 27%. that s maybe the first medication that we have that has such a positive result so far. but we have to be cautious about it. while the data is encouraging there, there were also some serious safety concerns in the phase iii trial. brain swelling and brain bleeding. those are certainly things the fda is going to evaluate if the drug comes up for approval. number eight, mental health. in a cnn kff poll this summer,
Bladder cancer patients whose blood contained circulating tumour DNA (ctDNA), treated with the immunotherapy drug named Atezolizumab, responded well to the drug.
the pandemic made it worse. so when we talk about providing access to students, we have to be bold in our actions. we have to make sure that not only in the k-12 space, higher ed, we re holding ourselves accountable for better results. that s what we re going to do at the department of education. and that s what this build back better agenda really does. it really focuses policy on addressing the inequities that are pervasive in our schools across the country. education secretary miguel cardona, it is great to see you. thank you for being with me this morning. appreciate your time. this morning, there is promising news about a potential new treatment for mild-to-moderate covid cases. the pharmaceutical company merck announced that a phase iii trial of their anti-viral drug reduced the risk of hospitalization or death by about 50%. merck says it will request emergency use authorization from the fda. it would be the first pill authorized to treat covid-19. we should note, this is not